Johnson & Johnson

NYSE:JNJ

Drug Manufacturers - General

Healthcare
$272.70 -1.96%

-$4.59 today

Market cap
$656.47B
Beta
0.26
P/E (TTM)
26.7
EPS (TTM)
$8.60
Dividend yield
2.28%
52W Low $149.04High $251.71

Volume 7.93M

Average 7.71M

JNJ Pre-Tax Margin

Income before tax as a percentage of revenue.

Johnson & JohnsonNYSE: JNJ

Pre-Tax Margin · Q3 FY2026 · quarter ended Sep 2026

Pre-tax margin narrows to 0.1%

Pre-tax margin was 0.1% in Q3 FY2026, down 31.1 pp from a year earlier. On a trailing-twelve-month basis it was 17.9%, down 16.3 pp year over year. Over 3 fiscal years it widened by 10.4 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
0.1%-26.5 pp QoQ
Last fiscal yearDec 2025
34.6%+15.8 pp YoY
LTMSep 2026
17.9%-16.3 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-31.1 pp——
1 year+15.8 pp——
3 years+10.4 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
34.6%
Year-over-year change
+15.8pp

Pre-Tax Margin vs competitors

How JNJ compares with its peers on the latest reported figures

  • JNJ's LTM Sep 2026 pre-tax margin of 17.9% is the 6th highest of the 11 companies compared; the peer median is 18.6%.
  • Its year-over-year change of -16.3 pp is the 9th highest of 11, against a peer median of +0.6 pp.
  • Over three fiscal years its change of +10.4 pp compares with a peer median of +3.1 pp.
JNJ Competitors Peer median
Pre-Tax Margin for JNJ and competitors
Company Period LTM level YoY 3-year change
NVSNovartis AGLTM Jun 202627.9% -0.4 pp+13.5 pp
AMGNAmgen Inc.LTM Jun 202627.0% +5.7 pp-3.5 pp
BMYBristol-Myers Squibb CompanyLTM Jun 202624.2% +10.4 pp+2.6 pp
AZNAstraZeneca PLCLTM Sep 202621.3% +1.6 pp+15.5 pp
ABBVAbbVie Inc.LTM Sep 202619.4% +16.6 pp-12.4 pp
JNJJohnson & JohnsonLTM Sep 202617.9% -16.3 pp+10.4 pp
GSKGSK plcLTM Jun 202617.8% +3.2 pp+3.5 pp
SNYSanofiLTM Jun 202610.6% -7.2 pp-11.7 pp
MRKMerck & Co., Inc.LTM Jun 20269.0% -21.1 pp+4.7 pp
PFEPfizer Inc.LTM Jun 20266.6% -9.9 pp-22.3 pp
GILDGilead Sciences, Inc.LTM Jun 2026-6.4% -31.4 pp+12.0 pp
Peer median (excluding JNJ) 18.6%+0.6 pp+3.1 pp

Competitors are the stored peer set for JNJ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue78.74B79.99B85.16B88.82B94.19B
Cost of Revenue23.4B24.6B26.55B27.47B30.26B
Gross Profit55.34B55.39B58.61B61.35B63.94B
Gross Margin70.3%69.3%68.8%69.1%67.9%
Research & Development14.28B14.14B15.09B17.23B14.67B
Selling, General & Admin20.12B20.25B20.11B21.97B23.68B
Operating Expenses34.4B34.38B35.2B39.2B38.34B
Depreciation & Amortization7.39B6.97B7.49B7.34B7.5B
EBITDA26.75B26.61B23.32B24.78B41.06B
EBITDA Margin34.0%33.3%27.4%27.9%43.6%
Operating Income20.94B21.01B23.41B22.15B25.6B
Operating Margin26.6%26.3%27.5%24.9%27.2%
Interest Income53M490M1.26B1.33B1.06B
Interest Expense183M276M772M755M971M
Other Income / Expenses(1.77B)(1.65B)(8.35B)(5.46B)6.99B
Income Before Tax19.18B19.36B15.06B16.69B32.58B
Pre-Tax Margin24.4%24.2%17.7%18.8%34.6%
Income Tax Expense1.38B2.99B1.74B2.62B5.78B
Net Income20.88B17.94B35.15B14.07B26.8B
Net Margin26.5%22.4%41.3%15.8%28.5%
EPS (Basic)7.936.8313.885.8411.03
EPS (Diluted)7.816.7313.725.7911.03
Weighted Avg Shares2.63B2.61B2.53B2.41B2.43B
Weighted Avg Shares (Diluted)2.67B2.66B2.56B2.43B2.43B

Johnson & Johnson

NYSE:JNJ

Intrinsic Alpha fair value

Locked

Current Price

$272.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.